Nymox

Nymox

March 10, 2005 11:58 ET

Breast Cancer Linked to Second Hand Smoke in New Report; Nymox -NASDAQ:NYMX- TobacAlert-TM- Provides an Accurate and Easy-to-Use Measure of Second Hand Smoke Exposure


NEWS RELEASE TRANSMITTED BY CCNMatthews

FOR: NYMOX

NASDAQ SYMBOL: NYMX

MARCH 10, 2005 - 11:58 ET

Breast Cancer Linked to Second Hand Smoke in New
Report; Nymox -NASDAQ:NYMX- TobacAlert-TM- Provides an
Accurate and Easy-to-Use Measure of Second Hand Smoke
Exposure

MAYWOOD, N.J.--(CCNMatthews - Mar 10, 2005) -

A new scientific report commissioned by the California Air Resources
Board (ARB) has concluded that women exposed to second hand smoke have a
higher risk of breast cancer. Reviewing earlier studies, the researchers
found a 26% increased risk across all studies with a 90% risk based on
newer studies with a better assessment of exposure.

TobacAlert™ is Nymox's revolutionary new product that allows
concerned individuals to determine second hand smoke exposure by
measuring the level of cotinine, a metabolite of nicotine, in urine. The
ARB report, Proposed Identification of Environmental Tobacco Smoke as a
Toxic Air Contaminant - March 2005, describes cotinine as the
"biological marker of choice" for determining second-hand smoke
exposure.

TobacAlert™ is a quick, accurate and easy to use test that can be
done almost anywhere, including at home, the workplace or school and
that requires no instruments to use. More information about
TobacAlert™ is available at www.tobacalert.com.

"I do not believe people understand how much of an impact their smoking
can have on those around them. TobacAlert™ provides everyone with a
simple, easy-to-use way of measuring exposure", said Brian Doyle,
Nymox's Global Sales Manager.

TobacAlert™ is available at approximately 5,400 CVS/pharmacy®
stores across the U.S. as well as online at www.cvs.com.

TobacAlert™ uses patented technology to provide a semi-quantitative
measure of cotinine, a by-product of the body's metabolism of nicotine.
Cotinine is widely accepted and commonly used in medical research and
public health studies to determine the extent of tobacco product
exposure. TobacAlert™ is intended only to assess an individual's
level of tobacco product exposure and not for any medical treatment
purposes.

More information about Nymox is available at www.nymox.com, email:
info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as
defined in the United States Private Securities Litigation Reform Act of
1995 that involve a number of risks and uncertainties. There can be no
assurance that such statements will prove to be accurate and the actual
results and future events could differ materially from management's
current expectations. Such factors are detailed from time to time in
Nymox's filings with the United States Securities and Exchange
Commission and other regulatory authorities.

-30-

Contact Information

  • FOR FURTHER INFORMATION PLEASE CONTACT:
    Nymox Pharmaceutical Corporation
    Roy Wolvin, 1-800-93NYMOX
    www.nymox.com